Table 6. Univariate analysis of progression-free survival of 40 newly diagnosed NSCLC patients according to clinicopathologic characteristics and lymphocyte subsets.
| Parameter | Median survival (months) | HR (95%CI) | P |
|---|---|---|---|
| Age (≥60 vs <60) | 17 vs 13 | 0.78(0.33-1.84) | 0.551 |
| Sex (Male vs Female) | 13 vs NA | 1.94(0.70-5.37) | 0.173 |
| ECOG PS (1-2 vs 0) | 11 vs 16 | 3.59(1.30-9.94) | 0.006 |
| Smoking (Previous/present vs Never) | 13 vs 13 | 1.33(0.54-3.27) | 0.521 |
| SUV (≥9.5 vs <9.5) | 13 vs NA | 4.14(0.85-20.11) | 0.051 |
| Histology (ADC vs SCC) | 13 vs 15 | 1.24(0.51-3.01) | 0.614 |
| Differentiation (Poor vs Well/moderate) | 8 vs 17 | 4.91(1.70-14.15) | 0.001 |
| Tumor Marker (Positive vs Negative) | 13 vs 15 | 1.93(0.64-5.80) | 0.213 |
| Tumor stage (T2-4 vs T1) | 13 vs NA | 1.70(0.57-5.03) | 0.312 |
| Nodal stage (N1-3 vs N0) | 12 vs 16 | 3.70(1.09-12.58) | 0.019 |
| AJCC stage (4 vs 1-3) | 10 vs 17 | 3.21(1.37-7.50) | 0.003 |
| Leukocyte (≥median vs <median) | 13 vs 13 | 0.96(0.38-2.38) | 0.919 |
| Lymphocyte (≥1.5 vs <1.5) | 14 vs 11 | 0.42(0.17-1.03) | 0.042 |
| NLR (≥2.54 vs <2.54 ) | 12 vs 16 | 2.66(1.01-7.05) | 0.033 |
| PLR (≥median vs <median) | 13 vs 13 | 1.34(0.55-3.29) | 0.500 |
| MLR (≥median vs <median) | 15 vs 13 | 1.21(0.50-2.94) | 0.655 |
| Treg (≥3.16 vs <3.16 ) | 12 vs 17 | 2.55(1.07-6.11) | 0.022 |
| CD3+ T cells (≥median vs <median) | 13 vs 13 | 0.99(0.43-2.31) | 0.989 |
| CD4+ T cells (≥median vs <median) | 13 vs 13 | 1.16(0.50-2.68) | 0.722 |
| CD8+ T cells (≥median vs <median) | 17 vs 13 | 0.86(0.37-2.01) | 0.720 |
| CD4/CD8 ratio(≥median vs <median) | 13 vs 17 | 1.53(0.65-3.60) | 0.302 |
| CD19+ B cells (≥median vs <median) | 11 vs 13 | 1.13(0.49-2.61) | 0.767 |
| NK (≥median vs <median) | 13 vs 13 | 0.97(0.42-2.27) | 0.945 |
| NKT (≥median vs <median) | 11 vs 15 | 1.57(0.67-3.68) | 0.271 |
| γδT (≥median vs <median) | 13 vs 15 | 1.49(0.63-3.49) | 0.335 |
| CD8+CD28+ T cells (≥median vs <median) | 13 vs 13 | 0.82(0.35-1.90) | 0.630 |
| CD8+CD28- T cells (≥median vs <median) | 17 vs 13 | 0.67(0.29-1.55) | 0.325 |
Abbreviations: NSCLC: non-small cell lung cancer; HR: hazard ratio; CI: confidence interval; Treg: regulatory T cells; SUV: standard uptake value; SCC: squamous cell carcinoma; ADC: adenocarcinoma; ECOG PS: Eastern Cooperative Oncology Group performance status; AJCC: American Joint Committee on Cancer; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; MLR: monocyte/lymphocyte ratio.